Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (131)	6/5/1999 11:22:00 AM
From: thebeach	Read Replies (1) \| Respond to of 356

Speaking of exciting things,congrats to Altarex management and shareholders for their latest great news.Maybe management at Procyon is close to landing a partner like that. The Globe and Mail reports in its Friday, June 4, edition that AltaRex advanced 18 cents to $1.03 yesterday on the Toronto Stock Exchange. The Globe's Market Movers column reports that the stock got legs yesterday on increased volume of 603,100 shares. The Alberta-based drug company, which is developing a drug for ovarian cancer, was rated "speculative buy" by First Marathon Securities analyst Cameron Groome. He set a short-term target price on the stock of $1.75. The junior company is expected to become marginally profitable next year, thanks to New Jersey-based partner Purdue Pharma's injection of cash and research and development funding that is expected to total $100-million (U.S.) In return, Purdue gets the right to market the first two products developed by AltaRex